Cellular Reprogramming is a prominent academic journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of cellular biology and biotechnology. With its ISSN 2152-4971 and E-ISSN 2152-4998, this journal provides an innovative platform for researchers and professionals to share groundbreaking research findings on cellular reprogramming, stem cell biology, and regenerative medicine. Established in 2010, and actively publishing until 2024, the journal is recognized for its contributions, evidenced by its categorizations in the Q3 and Q4 quartiles across several related fields, including biotechnology and developmental biology. This peer-reviewed journal not only supports open access to scientific literature but also aims to enhance interdisciplinary collaboration among scientists. With a growing impact in the realms of biochemistry, genetics, and molecular biology, Cellular Reprogramming remains an essential resource for the dissemination of pioneering research that could shape the future of cellular therapies.

Tissue Engineering Part A is a prestigious peer-reviewed journal published by MARY ANN LIEBERT, INC that focuses on innovative research and advancements within the field of tissue engineering and regenerative medicine. Since its inception in 2008, this journal has played a critical role in disseminating cutting-edge findings that bridge the gap between laboratory research and clinical application, underscoring its significance in the scientific community. With a diverse scope encompassing biochemistry, bioengineering, biomaterials, and biomedical engineering, the journal ranks notably in the Scopus database, holding a Q2 quartile status across multiple categories, thus reflecting its high impact on ongoing research and professional practice. For researchers, professionals, and students, Tissue Engineering Part A serves as an invaluable resource, offering insights into the latest methodologies and breakthroughs that drive the future of healthcare and therapeutic strategies. While primarily a subscription-based journal, it ensures that vital research is accessible to a broad audience of scientists and engineers committed to advancing the life sciences.

Current Stem Cell Reports, published by Springer Heidelberg, is an esteemed academic journal that has emerged as a pivotal resource in the fields of Cell Biology, Developmental Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has consistently contributed to the evolving discourse on stem cell research and its applications, providing a platform for innovative studies and reviews through 2024. With a notable impact indicated by its quartile rankings—Q2 in Developmental Biology and Genetics, and Q3 in Cell Biology and Molecular Biology—it engages a diverse audience of researchers, professionals, and students who seek high-quality, accessible research insights. Although offering a traditional access model, the content remains vital for those invested in understanding the implications of stem cell advancements. Located in Switzerland and operating from the heart of Heidelberg, this journal aspires to bridge gaps in knowledge and stimulate collaboration in the burgeoning field of stem cell science.

Tissue Engineering and Regenerative Medicine, published by the Korean Tissue Engineering Regenerative Medicine Society, is a distinguished journal focusing on the interdisciplinary fields of tissue engineering, regenerative medicine, and related biomedical innovations. With an ISSN of 1738-2696 and an E-ISSN of 2212-5469, this journal disseminates cutting-edge research and advancements pivotal to developing therapeutic strategies that improve tissue function and repair. As a testament to its scholarly impact, it holds a Q2 ranking in both Biomedical Engineering and Medicine (miscellaneous) categories, reflecting its influence and relevance within the scientific community, particularly with a Scopus rank placing it in the 82nd percentile among similar journals. Although the journal does not offer open access, it provides vital insights and knowledge to researchers, professionals, and students involved in the quest for innovative solutions in medical science and engineering. With its convergence years extending from 2008 to 2024, the journal continues to be an essential platform for the dissemination of high-quality research that drives the field forward.

BIOCELL is a distinguished peer-reviewed journal dedicated to the field of Cell Biology, published by TECH SCIENCE PRESS. Since its inception in 1995, the journal has been at the forefront of disseminating innovative research, with converged publication years extending from 1995 to 2013 and from 2015 to 2024. Although it currently holds a Q4 ranking in the Cell Biology category according to the 2023 category quartiles, BIOCELL aims to foster advancements by providing a platform for researchers, professionals, and students to share their findings in biochemistry, genetics, and molecular biology. The journal is available in both print (ISSN: 0327-9545) and digital formats (E-ISSN: 1667-5746) and seeks to attract contributions that enhance scholarly dialogue and understandings of cellular mechanisms and innovations. With a commitment to quality research and critical discourse, BIOCELL plays an important role in nurturing the scientific community within Argentina and beyond, offering vital insights that contribute to the advancement of the life sciences.

CYTOTECHNOLOGY, an esteemed journal published by Springer, stands as a vital resource in the fields of Bioengineering, Biomedical Engineering, and Biotechnology. With an impact factor reflective of its solid position within academia, this journal encompasses a broad scope dedicated to the advancement of cytotechnological research and applications from its inception in 1987 through to its latest volumes in 2024. Based in the Netherlands, it is committed to providing researchers, professionals, and students with high-quality, peer-reviewed articles that contribute to the understanding and innovations in cytotechnology. Although currently not open access, CYTOTECHNOLOGY has garnered a commendable reputation, holding Q3 rankings in multiple categories, indicating its relevance and influence within the scientific community. Researchers are encouraged to submit their cutting-edge findings to share insights that can spark further advancements in this dynamic field.

STEM CELLS AND DEVELOPMENT, published by Mary Ann Liebert, Inc., is a leading peer-reviewed journal dedicated to the rapidly advancing fields of stem cell biology and developmental science. With an ISSN of 1547-3287 and an E-ISSN of 1557-8534, the journal encompasses a broad range of topics central to understanding stem cells' roles in development and regeneration processes. It holds a prestigious standing within its category quartiles, ranking Q3 in Cell Biology, Q2 in Developmental Biology, and Q2 in Hematology for 2023. With its convergence from 2004 to 2024, STEM CELLS AND DEVELOPMENT fosters an innovative platform for researchers, professionals, and students to disseminate groundbreaking research, share insights, and explore novel therapeutic approaches. Open access options enhance the journal's visibility and accessibility, promoting a collaborative exchange of information among the scientific community. Positioned at the forefront of stem cell research and its applications, this journal is vital for anyone seeking to stay informed about the latest advancements and trends within these critical areas of study.

Cells, published by MDPI in Switzerland, is a leading open-access journal that has been disseminating groundbreaking research in the fields of Biochemistry, Genetics, and Molecular Biology since its inception in 2011. With an impressive E-ISSN of 2073-4409, the journal boasts a strong impact factor and ranks in the 84th percentile for Scopus ratings, underscoring its significance in advancing scientific knowledge. As a Q1-ranked journal in both 2023 and 2020, it serves as a premier platform for researchers, professionals, and students eager to explore innovative findings and methodologies. By providing unrestricted access to high-quality research, Cells plays a pivotal role in facilitating collaboration and inspiration within the global scientific community, making it an indispensable resource for anyone interested in cutting-edge discoveries in cellular biology.

CELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.

Journal of Tissue Engineering and Regenerative Medicine, published by WILEY, stands as a pivotal platform in the fields of biomaterials, biomedical engineering, and regenerative medicine. With an ISSN of 1932-6254 and an E-ISSN of 1932-7005, this journal, based in the United Kingdom, has consistently delivered high-quality research since its inception in 2006, converging critical insights through 2024. With an impressive citation profile reflected in its Scopus rankings—specifically a rank of #58 in Medicine and #75 in Biomedical Engineering—the journal is acknowledged for its substantial impact, as demonstrated by its competitive quartile standings in 2023. Notably, it maintains a Q3 ranking in Biomaterials and Q2 in both Biomedical Engineering and Medicine (miscellaneous), showcasing its influence and relevance in the rapidly evolving interplay between engineering and medicine. The journal serves as a vital resource for researchers and practitioners aiming to stay abreast of innovations and breakthroughs in regenerative therapies, tissue scaffolds, and biomaterials. While not an open-access publication, it fosters academic dialogue and knowledge dissemination that is crucial for advancing the field.